CA2629545A1 - Treating inflammatory disorders with antibodies to the alpha-7 nicotinic receptors - Google Patents

Treating inflammatory disorders with antibodies to the alpha-7 nicotinic receptors Download PDF

Info

Publication number
CA2629545A1
CA2629545A1 CA002629545A CA2629545A CA2629545A1 CA 2629545 A1 CA2629545 A1 CA 2629545A1 CA 002629545 A CA002629545 A CA 002629545A CA 2629545 A CA2629545 A CA 2629545A CA 2629545 A1 CA2629545 A1 CA 2629545A1
Authority
CA
Canada
Prior art keywords
fragment
seq
antibody
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002629545A
Other languages
English (en)
French (fr)
Inventor
Lihong Yang
Kevin J. Tracey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Feinstein Institutes for Medical Research
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2629545A1 publication Critical patent/CA2629545A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L12/00—Data switching networks
    • H04L12/02—Details
    • H04L12/16—Arrangements for providing special services to substations
    • H04L12/18—Arrangements for providing special services to substations for broadcast or conference, e.g. multicast
    • H04L12/1813—Arrangements for providing special services to substations for broadcast or conference, e.g. multicast for computer conferences, e.g. chat rooms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L51/00—User-to-user messaging in packet-switching networks, transmitted according to store-and-forward or real-time protocols, e.g. e-mail
    • H04L51/04—Real-time or near real-time messaging, e.g. instant messaging [IM]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Multimedia (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
CA002629545A 2005-11-15 2006-11-15 Treating inflammatory disorders with antibodies to the alpha-7 nicotinic receptors Abandoned CA2629545A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73704505P 2005-11-15 2005-11-15
US60/737,045 2005-11-15
PCT/US2006/044329 WO2007059203A2 (en) 2005-11-15 2006-11-15 Treating inflammatory disorders with antibodies to the alpha-7 nicotinic receptors

Publications (1)

Publication Number Publication Date
CA2629545A1 true CA2629545A1 (en) 2007-05-24

Family

ID=38007280

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002629545A Abandoned CA2629545A1 (en) 2005-11-15 2006-11-15 Treating inflammatory disorders with antibodies to the alpha-7 nicotinic receptors

Country Status (7)

Country Link
US (2) US8316104B2 (enExample)
EP (1) EP1957107A2 (enExample)
JP (1) JP5303279B2 (enExample)
CN (1) CN101355967A (enExample)
AU (1) AU2006315420B2 (enExample)
CA (1) CA2629545A1 (enExample)
WO (1) WO2007059203A2 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050149364A1 (en) * 2000-10-06 2005-07-07 Ombrellaro Mark P. Multifunction telemedicine software with integrated electronic medical record
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7599989B2 (en) * 2005-01-24 2009-10-06 Microsoft Corporation System and method for gathering and reporting screen resolutions of attendees of a collaboration session
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
EP1954718B1 (en) 2005-11-30 2014-09-03 AbbVie Inc. Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
US20070268294A1 (en) * 2006-05-16 2007-11-22 Stephen Troy Eagen Apparatus and method for topology navigation and change awareness
US20070294404A1 (en) * 2006-06-15 2007-12-20 International Business Machines Corporation Method and system for authorization and access control delegation in an on demand grid environment
US20080065999A1 (en) * 2006-09-13 2008-03-13 Majors Kenneth D Conferencing system with document access
US8418069B2 (en) * 2006-09-29 2013-04-09 International Business Machines Corporation Spinning off chat threads
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US9195996B1 (en) 2006-12-27 2015-11-24 Qurio Holdings, Inc. System and method for classification of communication sessions in a social network
EP2486928A1 (en) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8595357B2 (en) 2007-03-01 2013-11-26 Cisco Technology, Inc. System and method for hosted network management
US9274847B2 (en) * 2007-05-04 2016-03-01 Microsoft Technology Licensing, Llc Resource management platform
US8782527B2 (en) 2007-06-27 2014-07-15 Microsoft Corp. Collaborative phone-based file exchange
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
US7822841B2 (en) * 2007-10-30 2010-10-26 Modern Grids, Inc. Method and system for hosting multiple, customized computing clusters
EP2056563B1 (en) * 2007-11-05 2012-09-26 Alcatel Lucent Peer-to-peer network
US9117211B2 (en) * 2008-07-24 2015-08-25 International Business Machines Corporation System and method for correlating questions and answers in an instant messaging environment
US8655950B2 (en) * 2008-08-06 2014-02-18 International Business Machines Corporation Contextual awareness in real time collaborative activity alerts
US8838532B2 (en) * 2008-12-24 2014-09-16 At&T Intellectual Property I, L.P. Collaborative self-service contact architecture with automatic blog content mapping capability
GB2469501B (en) * 2009-04-16 2012-01-04 Appshare Ltd Method and system for network-based collaboration
US9390156B2 (en) * 2009-06-29 2016-07-12 International Business Machines Corporation Distributed directory environment using clustered LDAP servers
US20110142221A1 (en) * 2009-12-15 2011-06-16 At&T Intellectual Property I, L.P. System and method for automated group calling service based on key words
US8508575B2 (en) * 2010-03-31 2013-08-13 Sony Corporation Television system, television set and method for operating a television system
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
US8482593B2 (en) 2010-05-12 2013-07-09 Blue Jeans Network, Inc. Systems and methods for scalable composition of media streams for real-time multimedia communication
US9081633B2 (en) 2010-05-24 2015-07-14 Microsoft Technology Licensing, Llc Remote application connection sharing
EP2589183B1 (en) * 2010-06-29 2014-03-26 Telefonaktiebolaget L M Ericsson (publ) A method and an apparatus for evaluating network performance
US8558868B2 (en) * 2010-07-01 2013-10-15 Cisco Technology, Inc. Conference participant visualization
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
US9124757B2 (en) 2010-10-04 2015-09-01 Blue Jeans Networks, Inc. Systems and methods for error resilient scheme for low latency H.264 video coding
US8380845B2 (en) 2010-10-08 2013-02-19 Microsoft Corporation Providing a monitoring service in a cloud-based computing environment
WO2012048347A1 (en) * 2010-10-08 2012-04-12 Brian Lee Moffat Private data sharing system
US8843632B2 (en) 2010-10-11 2014-09-23 Microsoft Corporation Allocation of resources between web services in a composite service
US8959219B2 (en) 2010-10-18 2015-02-17 Microsoft Technology Licensing, Llc Dynamic rerouting of service requests between service endpoints for web services in a composite service
US8874787B2 (en) 2010-10-20 2014-10-28 Microsoft Corporation Optimized consumption of third-party web services in a composite service
US9300705B2 (en) 2011-05-11 2016-03-29 Blue Jeans Network Methods and systems for interfacing heterogeneous endpoints and web-based media sources in a video conference
US9369673B2 (en) 2011-05-11 2016-06-14 Blue Jeans Network Methods and systems for using a mobile device to join a video conference endpoint into a video conference
US9159037B2 (en) 2011-06-14 2015-10-13 Genesys Telecommunications Laboratories, Inc. Context aware interaction
US9195971B2 (en) * 2011-07-12 2015-11-24 Salesforce.Com, Inc. Method and system for planning a meeting in a cloud computing environment
EP2555141A1 (en) * 2011-08-03 2013-02-06 Alcatel Lucent A method, a system, a server, a control element, a computer program and a computer program product for operating a power grid having decentralized control elements
US20130080513A1 (en) * 2011-09-28 2013-03-28 Jeremy Debate Multi-party communication sessions via broadcast notification network
US20130097244A1 (en) 2011-09-30 2013-04-18 Clearone Communications, Inc. Unified communications bridging architecture
DE102011117777B3 (de) * 2011-11-01 2013-01-31 Markus Lehnert System und Verfahren zur Bestimmung eines bevorzugten Kommunikationskanal
EP2629475B1 (en) 2012-02-16 2019-08-28 BlackBerry Limited Method and system for obtaining availability status for multiple sip users
JP6102575B2 (ja) * 2013-07-02 2017-03-29 富士通株式会社 性能測定方法、性能測定プログラム及び性能測定装置
US9392079B2 (en) 2013-07-19 2016-07-12 International Business Machines Corporation Directory service discovery and/or learning
US20150077509A1 (en) 2013-07-29 2015-03-19 ClearOne Inc. System for a Virtual Multipoint Control Unit for Unified Communications
US20170034235A1 (en) * 2015-07-27 2017-02-02 Browan Communications Inc. Electronic device, communication system and method for transmitting/receiving audio and video data
US10771508B2 (en) 2016-01-19 2020-09-08 Nadejda Sarmova Systems and methods for establishing a virtual shared experience for media playback
US9800931B1 (en) * 2016-06-08 2017-10-24 Cisco Technology, Inc. Adaptive screen layout for video conferencing
US9712570B1 (en) * 2016-09-28 2017-07-18 Atlassian Pty Ltd Dynamic adaptation to increased SFU load by disabling video streams
US11440970B2 (en) * 2017-08-15 2022-09-13 Antidote Therapeutics, Inc. Nicotine-binding antibodies
CN110151762A (zh) * 2019-05-19 2019-08-23 青海大学 一种噻虫啉的新用途
US11750733B2 (en) 2021-04-19 2023-09-05 Meta Platforms Technologies, Llc Automatically switching between video and other calling modes based on sensor data from a wrist-wearable device, and methods of use thereof
EP4383733A3 (en) 2021-04-19 2024-07-31 Meta Platforms Technologies, LLC Wrist-wearable device for automatically switching between video and other calling modes based on sensor data at the wrist-wearable device, head-worn wearable devices for use therewith and for coordinated video capturing with the wrist-wearable device, and methods of use thereof
CN120457144A (zh) * 2022-11-10 2025-08-08 巴斯德研究所 产生作为α7烟碱乙酰胆碱受体的沉默和正变构调节剂的抗体

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977144A (en) 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
DE69332641T2 (de) 1992-08-31 2003-11-27 University Of Florida Research Foundation, Inc. Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystems
DK0777671T3 (da) 1994-08-24 2000-07-24 Astrazeneca Ab Spiro-azabicykliske forbindelser
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US7266686B1 (en) * 1996-05-09 2007-09-04 Two-Way Media Llc Multicasting method and apparatus
FR2756826B1 (fr) 1996-12-05 1999-01-08 Adir Nouveaux derives tetrahydropyridiniques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6323000B2 (en) 1996-12-20 2001-11-27 Clark A. Briggs Variant human α7 acetylcholine receptor subunit, and methods of production and uses thereof
JP2002502383A (ja) 1997-05-30 2002-01-22 ニューロサーアチ・アクティーゼルスカブ ニコチンＡＣｈレセプターに於けるコリン作動性リガンドとしての９−アザビシクロ（３．３．１）ノン−２−エン及びノナン誘導体
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
JP2003512290A (ja) 1997-09-10 2003-04-02 メルク エンド カムパニー インコーポレーテッド 家畜抗菌剤としての８ａ−アザライド
US6484196B1 (en) * 1998-03-20 2002-11-19 Advanced Web Solutions Internet messaging system and method for use in computer networks
US6459682B1 (en) * 1998-04-07 2002-10-01 International Business Machines Corporation Architecture for supporting service level agreements in an IP network
WO1999062505A2 (en) 1998-06-01 1999-12-09 Ortho-Mcneil Pharmaceutical, Inc. Method for treating neurodegenerative disorders
FR2786770B1 (fr) 1998-12-04 2001-01-19 Synthelabo Derives de 1,4-diazabicyclo[3.2.2.]nonane, leur preparation et leur application en therapeutique
FR2786769B1 (fr) 1998-12-04 2002-10-25 Synthelabo Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique
US6432975B1 (en) 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
FR2790474B1 (fr) 1999-03-05 2001-04-06 Synthelabo Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
GB2349055B (en) * 1999-04-16 2004-03-24 Mitel Corp Virtual meeting rooms with spatial audio
JP2002543201A (ja) 1999-05-04 2002-12-17 ニューロサーチ、アクティーゼルスカブ ヘテロアリールジアザビシクロアルカン類、その製造方法及びその使用方法
US20040038875A1 (en) 2000-03-29 2004-02-26 Greenfield Susan Adele Alpha 7nicotinic receptor screening assays
US6751404B1 (en) * 2000-04-13 2004-06-15 Forgent Networks, Inc. Method and apparatus for detecting processor congestion during audio and video decode
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
US6976066B1 (en) * 2000-05-22 2005-12-13 Microsoft Corporation Network and method for implementing network platform services for a computing device
US6610713B2 (en) 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
JP2002007294A (ja) * 2000-06-22 2002-01-11 Canon Inc 画像配信システム及び方法並びに記憶媒体
AU6583101A (en) 2000-07-04 2002-01-14 Neurosearch As Aryl and heteroaryl diazabicycloalkanes, their preparation and use
JP4616971B2 (ja) 2000-07-18 2011-01-19 田辺三菱製薬株式会社 １−アザビシクロアルカン化合物およびその医薬用途
US20030037109A1 (en) * 2000-08-11 2003-02-20 Newman Harvey B. Virtual room videoconferencing system
WO2002016356A2 (en) 2000-08-18 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
WO2002016358A2 (en) 2000-08-18 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
WO2002016357A2 (en) 2000-08-18 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
US6492385B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
WO2002017358A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
US6599916B2 (en) 2000-08-21 2003-07-29 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
US7158534B2 (en) * 2000-11-30 2007-01-02 Imajet Communications, Inc. Unified distributed architecture for a multi-point video conference and interactive broadcast systems
ATE385497T1 (de) 2000-12-01 2008-02-15 Neurosearch As 3-substituierte quinuclidin-derivate und deren verwendung als nikotinischen agonisten
US7130883B2 (en) * 2000-12-29 2006-10-31 Webex Communications, Inc. Distributed network system architecture for collaborative computing
US20020086871A1 (en) 2000-12-29 2002-07-04 O'neill Brian Thomas Pharmaceutical composition for the treatment of CNS and other disorders
WO2002057275A1 (en) 2001-01-17 2002-07-25 University Of Kentucky Research Foundation Boron-containing nicotine analogs for use in the treatment of cns pathologies
US6479172B2 (en) 2001-01-26 2002-11-12 Xerox Corporation Electroluminescent (EL) devices
US20020133611A1 (en) * 2001-03-16 2002-09-19 Eddy Gorsuch System and method for facilitating real-time, multi-point communications over an electronic network
CA2341952A1 (en) 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
US6569865B2 (en) 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
WO2003018585A1 (en) 2001-08-24 2003-03-06 Pharmacia & Upjohn Company Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease
DE60218493D1 (de) 2001-09-12 2007-04-12 Pharmacia & Upjohn Co Llc Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
KR100614900B1 (ko) 2001-10-02 2006-08-25 파마시아 앤드 업존 캄파니 엘엘씨 질병의 치료를 위한 아자비시클릭-치환된 융합-헤테로아릴화합물
US20040259909A1 (en) 2001-10-16 2004-12-23 Mccarthy Dennis Treatment of fibromyalgia syndrome
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
EP1442037A1 (en) 2001-11-09 2004-08-04 PHARMACIA & UPJOHN COMPANY Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands
KR100411251B1 (ko) * 2001-11-28 2003-12-18 한국전자통신연구원 제한조건을 만족하는 다중 경로 배정방법
DE10211415A1 (de) 2002-03-15 2003-09-25 Bayer Ag Bicyclische N-Biarylamide
US7238715B2 (en) 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
DE60317564T2 (de) * 2002-12-06 2008-10-23 The Feinstein Institute For Medical Research Hemmung von entzündungen unter verwendung von alpha-7-rezeptor verbindenden cholinergen agonisten
US7680920B2 (en) * 2003-03-24 2010-03-16 Netiq Corporation Methods, systems and computer program products for evaluating network performance using diagnostic rules identifying performance data to be collected
US7415527B2 (en) * 2003-06-13 2008-08-19 Satyam Computer Services Limited Of Mayfair Centre System and method for piecewise streaming of video using a dedicated overlay network
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system

Also Published As

Publication number Publication date
CN101355967A (zh) 2009-01-28
AU2006315420B2 (en) 2010-07-15
JP2009515982A (ja) 2009-04-16
US20090324588A1 (en) 2009-12-31
US8316104B2 (en) 2012-11-20
EP1957107A2 (en) 2008-08-20
WO2007059203A3 (en) 2007-07-19
US8524866B2 (en) 2013-09-03
US20070156813A1 (en) 2007-07-05
WO2007059203A2 (en) 2007-05-24
JP5303279B2 (ja) 2013-10-02
AU2006315420A1 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
AU2006315420B2 (en) Treating inflammatory disorders with antibodies to the alpha-7 nicotinic receptors
US20240294631A1 (en) Antibodies directed against interleukin-33 (il-33)
KR102759268B1 (ko) 림프구 활성화 유전자 3(lag-3)에 대한 항체
KR102645242B1 (ko) 염증 질환의 치료 방법
KR102755473B1 (ko) 인간 il-4ra에 대한 항체 및 이의 용도
PT2115003E (pt) Anticorpos humanos que se ligam ao ligando 4 semelhante ao ligando delta humano
US20090123456A1 (en) Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
CN101952316B (zh) 用于治疗炎性关节障碍的钙黏着蛋白-11 ec1结构域拮抗剂
WO2017147742A1 (en) Gfral receptor therapies
CN102585002A (zh) 人il-6受体的高亲和力抗体
KR20180029106A (ko) 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 모노클로날 항체
WO2008103849A2 (en) Methods and compounds for lymphoma cell detection and isolation
KR20170138494A (ko) 항-ｔｙｒ０３ 항체 및 이의 용도
JP2022547850A (ja) 抗ｔｉｇｉｔ免疫阻害剤及び応用
KR20080059449A (ko) 치료용 약제
KR20230146591A (ko) 신규 항pad4 항체
CN109384845B (zh) 一种cd40单克隆抗体、其制备方法及其应用
JP4198882B2 (ja) Ｃ型肝炎レセプタータンパク質ｃｄ８１
WO2014169494A1 (zh) 特异性识别egfr突变蛋白的单克隆抗体、制备方法及其应用
CN114127110B (zh) 抗cgrp抗体及其应用
WO2025160964A1 (zh) 一种trpm3抗体、制备其的方法及应用
CN110922483B (zh) 抗ccr5抗体及其在治疗肿瘤中的应用
CN119604529A (zh) 抗体、其抗原结合片段及其药物用途
WO2024263685A2 (en) Analgesic compositions and methods thereof
WO2024163658A1 (en) Compositions and methods for anti-pacap igg4 antibodies

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20121115